<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29094" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cutaneous Squamous Cell Carcinoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hadian</surname>
            <given-names>Yasmin</given-names>
          </name>
          <aff>t Goodman Dermatology, Philadelphia COM, Roswell, GA</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Howell</surname>
            <given-names>Jesse Y.</given-names>
          </name>
          <aff>Geisinger Health Systems</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ramsey</surname>
            <given-names>Michael L.</given-names>
          </name>
          <aff>Geisinger Health System</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Buckley</surname>
            <given-names>Chris</given-names>
          </name>
          <aff>Philadelphia College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yasmin Hadian declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jesse Howell declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Ramsey declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chris Buckley declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29094.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Squamous cell carcinoma is the second most common skin malignancy in the United States, and its incidence steadily rises each year, posing a significant public health concern. Mortality rates for cutaneous squamous cell carcinoma are comparable to those of melanoma, renal carcinoma, and oropharyngeal carcinoma in the central and southern regions of the United States. Timely surveillance, early diagnosis, and prompt treatment are critical to minimize morbidity and mortality risks.&#x000a0;Although surgical excision remains the cornerstone of treatment, ongoing research brings novel therapeutic approaches. In addition, nonsurgical options, such as radiation therapy, topical creams, cryotherapy, photodynamic therapy, and laser ablation, are available, especially for patients unsuitable for surgery. However, these nonsurgical treatments often have higher recurrence rates.</p>
        <p>Regular skin examinations and frequent follow-ups are recommended by healthcare providers, particularly for high-risk patients, to facilitate early detection and treatment, highlighting the importance of collaborative care for optimal management. Diagnosis usually requires a skin biopsy, with advanced cases often necessitating additional imaging and sentinel lymph node biopsy.&#x000a0;This activity covers the etiology, epidemiology, pathophysiology, histopathological subtypes, clinical features, and management options for cutaneous squamous cell carcinoma. This activity emphasizes the critical role of photoprotection in reducing the risk of developing cutaneous squamous cell carcinoma due to its strong association with UV radiation.&#x000a0;Therefore, this activity underscores the importance of interprofessional collaboration among healthcare providers in counseling patients on preventive measures, such as practicing photoprotection through sun avoidance, using SPF 30 sunscreen, and wearing protective clothing and sunglasses.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical features and risk factors associated with cutaneous squamous cell carcinoma.</p></list-item><list-item><p>Implement evidence-based treatment strategies tailored to the subtype and stage of the carcinoma.</p></list-item><list-item><p>Select appropriate imaging and biopsy techniques for advanced cases requiring further evaluation.</p></list-item><list-item><p>Collaborate with dermatologists, oncologists, and other specialists to coordinate multidisciplinary care for comprehensive management of advanced cases and to optimize patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29094&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29094">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29094.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Squamous cell carcinoma is the second most common cutaneous malignancy in the United States. Risk factors include immunosuppression, chronic wounds, fair skin, male gender, older age, several genetic syndromes, environmental exposures such as UV radiation, and a previous history of squamous cell carcinoma. Although metastasis is rare, the most common site of metastasis is the lymph nodes. As the incidence steadily increases, posing a significant public health concern, timely surveillance, early diagnosis, and prompt treatment are essential to minimize morbidity and mortality risks. Photoprotection and frequent full-body skin exams are recommended. While most cases are treated with surgical excision, novel therapeutic modalities continue to emerge. Systemic oncologic therapy and radiation therapy may be warranted for more advanced cases.<xref ref-type="bibr" rid="article-29094.r1">[1]</xref><xref ref-type="bibr" rid="article-29094.r2">[2]</xref><xref ref-type="bibr" rid="article-29094.r3">[3]</xref><xref ref-type="bibr" rid="article-29094.r4">[4]</xref></p>
      </sec>
      <sec id="article-29094.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The development of cutaneous squamous cell carcinoma is associated with the following&#x000a0;risk&#x000a0;factors and etiologies:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>UV radiation: UVA and UVB are the most significant risk factors.</p>
          </list-item>
          <list-item>
            <p>Environmental exposures other than UV radiation: This includes arsenic, polycyclic aromatic hydrocarbons, nitrosamines, alkylating agents, and ionizing radiation.</p>
          </list-item>
          <list-item>
            <p>Demographic factors: Fair skin, male, and older age.</p>
          </list-item>
          <list-item>
            <p>Immunosuppressed state: Iatrogenic, leukemia, and AIDS.</p>
          </list-item>
          <list-item>
            <p>Genetic syndromes: Huriez syndrome, xeroderma pigmentosa, oculocutaneous albinism, dyskeratosis congenita, Rothmund-Thomson syndrome, Werner syndrome, Bloom syndrome, dystrophic epidermolysis bullosa, epidermodysplasia verruciformis, Fanconi anemia,&#x000a0;keratitis-ichthyosis-deafness syndrome, and genetic immunodeficiency syndromes.</p>
          </list-item>
          <list-item>
            <p>Preexisting lesions: Chronic wounds (Marjolin ulcer), human papillomavirus, actinic keratosis, porokeratosis, lichen sclerosus et atrophicus, hypertrophic or oral lichen planus, and discoid cutaneous lupus erythematosus.</p>
          </list-item>
          <list-item>
            <p>Medications: BRAF inhibitors, vismodegib, and voriconazole, immunosuppressive agents.<xref ref-type="bibr" rid="article-29094.r5">[5]</xref><xref ref-type="bibr" rid="article-29094.r6">[6]</xref><xref ref-type="bibr" rid="article-29094.r7">[7]</xref><xref ref-type="bibr" rid="article-29094.r8">[8]</xref><xref ref-type="bibr" rid="article-29094.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29094.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Squamous cell carcinoma is the second most common cutaneous malignancy in the United States. The incidence of this condition has steadily increased, with a nearly 3-fold rise reported from the 1970s to the early 2000s.<xref ref-type="bibr" rid="article-29094.r10">[10]</xref>&#x000a0;In 2012, the incidence of cutaneous squamous cell carcinoma was estimated at 140 per 100,000 American men and 50 per 100,000 American women.&#x000a0;The mortality rate is approximately 1% to 2%.<xref ref-type="bibr" rid="article-29094.r11">[11]</xref>&#x000a0;However, in the southern and central regions of the United States, the mortality rate is similar to that of melanoma and renal and oropharyngeal carcinoma.<xref ref-type="bibr" rid="article-29094.r12">[12]</xref>&#x000a0;The prevalence is higher among men, fair-skinned individuals, and older age groups.</p>
      </sec>
      <sec id="article-29094.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Cutaneous squamous cell carcinoma is derived from the keratinocytes. A mutation in the <italic toggle="yes">tp53</italic> tumor suppressor gene is the most common genetic abnormality observed in both squamous cell carcinoma and its precursor, actinic keratosis. Decreased immunosurveillance in immunosuppressed patients may further potentiate tumor growth. For instance, patients with solid organ transplants on immunosuppressive therapy have a 65- to 250-fold increased risk of developing squamous cell carcinoma compared to the general population.<xref ref-type="bibr" rid="article-29094.r1">[1]</xref></p>
      </sec>
      <sec id="article-29094.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The histological subtypes of squamous cell carcinoma include squamous cell carcinoma in situ/Bowen disease, acantholytic/adenoid/pseudoglandular, clear cell, sarcomatoid/spindle cell, desmoplastic, keratoacanthoma, and verrucous carcinoma. Tumors classically consist of atypical keratinocytes with abundant eosinophilic or pink,&#x000a0;glassy cytoplasm. Other common findings include parakeratosis, intercellular bridging, and keratin pearls (see <bold>Image.</bold>&#x000a0;Histological Slide of Cutaneous Squamous Cell Carcinoma).&#x000a0;High-risk histological subtypes include acantholytic, sarcomatoid, and desmoplastic.</p>
        <p>
<bold>Squamous Cell Carcinoma In Situ</bold>
</p>
        <p>This subtype, also known as Bowen disease, is characterized by full-thickness keratinocyte atypia that has not invaded beyond the basal layer of the epidermis. In contrast, invasive squamous cell carcinoma has penetrated beyond the basal layer (see&#x000a0;<bold>Image.</bold>&#x000a0;Histological Slide of Squamous Cell Carcinoma, In Situ).&#x000a0;The basal layer is often intact, forming the "eyeliner sign."&#x000a0;</p>
        <p>
<bold>Acantholytic/Adenoid/Pseudoglandular</bold>
</p>
        <p>This subtype is characterized by clefting around nests or cords of plump, polygonal tumor cells, creating a glandular appearance (see&#x000a0;<bold>Image.</bold>&#x000a0;Histological Slide of Squamous Cell Carcinoma, Acantholytic). Clefting is due to desmosomal disruption. In contrast to tumors of true glandular origin, such as adenosquamous carcinoma, the carcinoembryonic antigen (CEA) staining is negative.</p>
        <p>
<bold>Clear Cell</bold>
</p>
        <p>This subtype is characterized by clear or pale tumor cells that may or may not demonstrate an epidermal connection (see&#x000a0;<bold>Image.</bold>&#x000a0;Histological Slide of&#x000a0;Squamous Cell Carcinoma, Clear Cell).&#x000a0;Histological differentials include clear cell acanthoma and renal cell carcinoma.</p>
        <p>
<bold>Sarcomatoid/Spindle Cell</bold>
</p>
        <p>This subtype is characterized by spindle-shaped keratinocytes with pleomorphic nuclei arranged haphazardly throughout the dermis in a typically infiltrative pattern (see&#x000a0;<bold>Image.</bold>&#x000a0;Histological Slide of Squamous Cell Carcinoma, Sarcomatoid). Numerous mitotic figures may be observed. Atypical fibroxanthoma is an important histological differential that typically stains negative for p63 and p40, unlike sarcomatoid or spindle squamous cell carcinoma (see&#x000a0;<bold>Image.</bold>&#x000a0;Histological Slide of Squamous Cell Carcinoma, Positive p40 Stain).&#x000a0;Immunohistochemistry with p40&#x000a0;is more specific than p63.&#x000a0;</p>
        <p><bold>Desmoplastic</bold>&#x000a0;</p>
        <p>This subtype may appear similar to the sarcomatoid or spindle cell variant of squamous cell carcinoma. However,&#x000a0;desmoplastic carcinoma is characterized by a desmoplastic (densely collagenous) stroma in more than 30% of the tumor. Perineural invasion is frequently reported. Desmoplastic melanoma is also considered in the histological differential diagnosis. Unlike desmoplastic melanoma, desmoplastic squamous cell carcinoma typically stains positive for p63 and negative for SOX10 and S100.</p>
        <p>
<bold>Keratoacanthoma</bold>
</p>
        <p>This subtype is characterized by a crateriform invagination filled with keratin (see&#x000a0;<bold>Image.</bold>&#x000a0;Histological Slide of&#x000a0;Squamous Cell Carcinoma, Keratoacanthoma). The tumor cells are typically well-differentiated.</p>
        <p>
<bold>Verrucous Carcinoma</bold>
</p>
        <p>This subtype is characterized by verruciform acanthosis with blunt, broad projections that push into, rather than infiltrate, the dermis. Human papillomavirus-related cytomorphology in verrucous carcinoma is less pronounced compared to benign warts.<xref ref-type="bibr" rid="article-29094.r2">[2]</xref><xref ref-type="bibr" rid="article-29094.r13">[13]</xref><xref ref-type="bibr" rid="article-29094.r14">[14]</xref><xref ref-type="bibr" rid="article-29094.r15">[15]</xref></p>
      </sec>
      <sec id="article-29094.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Cutaneous squamous cell carcinoma is typically characterized by a scaly, erythematous, or hyperpigmented papule or plaque. Some cases may exhibit ulceration, fungating features, or pain (see&#x000a0;<bold>Image.</bold>&#x000a0;Cutaneous Squamous Cell Carcinoma). Due to its strong association with UV radiation exposure, many cases arise in sun-damaged skin. This tumor can also develop from preexisting lesions such as actinic keratosis, chronic wounds (Marjolin ulcer), human papillomavirus infection, porokeratosis, lichen sclerosus et atrophicus, hypertrophic or oral lichen planus, and discoid cutaneous lupus erythematosus.<xref ref-type="bibr" rid="article-29094.r7">[7]</xref><xref ref-type="bibr" rid="article-29094.r8">[8]</xref><xref ref-type="bibr" rid="article-29094.r9">[9]</xref><xref ref-type="bibr" rid="article-29094.r16">[16]</xref><xref ref-type="bibr" rid="article-29094.r17">[17]</xref></p>
      </sec>
      <sec id="article-29094.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A skin biopsy is&#x000a0;necessary to confirm the diagnosis of cutaneous squamous cell carcinoma. Additionally, sentinel lymph node biopsy and/or radiological evaluation for lymph node metastasis with computed tomography or ultrasound is recommended in cases classified as stage&#x000a0;T2B-T3 according to the Brigham and Women's Hospital (BWH) staging system or stage T4 according to the American Joint Committee on Cancer 8th ed. (AJCC-8) staging&#x000a0;system. Case-by-case consideration is needed for AJCC-8 stage T2-3. For patients presenting with palpable lymphadenopathy, fine-needle aspiration or biopsy of the lymph node(s) is advised.<xref ref-type="bibr" rid="article-29094.r1">[1]</xref><xref ref-type="bibr" rid="article-29094.r3">[3]</xref></p>
      </sec>
      <sec id="article-29094.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The preferred therapeutic intervention for cutaneous squamous cell carcinoma is surgical excision. Mohs micrographic surgery is preferred in cases that meet appropriate use criteria (AUC). Factors listed in the AUC include, but are not limited to, clinical diameter of the apparent lesion greater than 2 cm, high-risk histological features, recurrent versus primary lesions, cosmetically sensitive and/or high-risk anatomical locations such as the ears, lips, nose, and periocular regions, as well as immunosuppression.<xref ref-type="bibr" rid="article-29094.r18">[18]</xref> The&#x000a0;reported 5-year recurrence rate for Mohs micrographic surgery is approximately 3.1%, whereas standard excision with 4 to 6 mm margins has a reported recurrence rate of approximately 8.1%. Mohs micrographic surgery offers a significantly greater risk reduction compared to standard excision, particularly in cases with high-risk features. For example, locally recurrent (previously treated) lesions showed a 10% recurrence rate with Mohs micrographic surgery and a 23.3% recurrence rate with standard excision.<xref ref-type="bibr" rid="article-29094.r19">[19]</xref> Electrodessication and curettage are alternative options for in situ cases, albeit with slightly higher recurrence rates compared to Mohs micrographic surgery and standard excision.<xref ref-type="bibr" rid="article-29094.r20">[20]</xref>&#x000a0;</p>
        <p>For patients who are not suitable for surgery, options for treating cutaneous squamous cell carcinoma include superficial radiation therapy, 5-fluorouracil cream, imiquimod cream, cryotherapy, photodynamic therapy, and/or ablative laser. However, these treatments often result in higher recurrence rates and lack histologically confirmed clearance.<xref ref-type="bibr" rid="article-29094.r21">[21]</xref><xref ref-type="bibr" rid="article-29094.r22">[22]</xref>&#x000a0;Lymphadenectomy&#x000a0;of the associated nodal basin is recommended for cases with positive lymph nodes. Radiation therapy is typically used for cases involving large-caliber nerve invasion, lymphovascular invasion, multiple lymph nodes, or extracapsular extension. Adjuvant systemic oncologic therapy for advanced cases may include chemotherapy, epidermal growth factor inhibitors, or immunotherapy.<xref ref-type="bibr" rid="article-29094.r3">[3]</xref>&#x000a0;Recently, novel immunotherapeutic agents have emerged, showing superior clinical outcomes compared to traditional systemic therapies.<xref ref-type="bibr" rid="article-29094.r23">[23]</xref><xref ref-type="bibr" rid="article-29094.r24">[24]</xref></p>
      </sec>
      <sec id="article-29094.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses include but are not limited to:</p>
        <list list-type="bullet">
          <list-item>
            <p>Basal cell carcinoma</p>
          </list-item>
          <list-item>
            <p>Melanoma</p>
          </list-item>
          <list-item>
            <p>Extramammary Paget disease</p>
          </list-item>
          <list-item>
            <p>Actinic keratosis</p>
          </list-item>
          <list-item>
            <p>Seborrheic keratosis</p>
          </list-item>
          <list-item>
            <p>Porokeratosis</p>
          </list-item>
          <list-item>
            <p>Lichen planus-like keratosis</p>
          </list-item>
          <list-item>
            <p>Verruca</p>
          </list-item>
          <list-item>
            <p>Psoriasis</p>
          </list-item>
          <list-item>
            <p>Nummular dermatitis</p>
          </list-item>
          <list-item>
            <p>Lichen planus</p>
          </list-item>
          <list-item>
            <p>Lichen sclerosus et atrophicus</p>
          </list-item>
          <list-item>
            <p>Discoid cutaneous lupus erythematosus&#x000a0;<xref ref-type="bibr" rid="article-29094.r16">[16]</xref><xref ref-type="bibr" rid="article-29094.r17">[17]</xref><xref ref-type="bibr" rid="article-29094.r25">[25]</xref><xref ref-type="bibr" rid="article-29094.r26">[26]</xref><xref ref-type="bibr" rid="article-29094.r27">[27]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29094.s11" sec-type="Staging">
        <title>Staging</title>
        <p>The staging categories for cutaneous squamous cell carcinoma as per BWH and AJCC-8 are listed below.</p>
        <p><bold>BWH Staging System</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage T1: 0&#x000a0;high-risk features</p>
          </list-item>
          <list-item>
            <p>Stage T2A: 1&#x000a0;high-risk feature</p>
          </list-item>
          <list-item>
            <p>Stage T2B: 2 to 3&#x000a0;high-risk features</p>
          </list-item>
          <list-item>
            <p>Stage T3: 4 or more high-risk features or bone invasion</p>
          </list-item>
          <list-item>
            <p>High-risk&#x000a0;features, as defined by BWH, include:
<list list-type="bullet"><list-item><p>Tumor diameter of at least 2 cm</p></list-item><list-item><p>Histologically poor differentiation</p></list-item><list-item><p>Perineural invasion of at least 0.1 mm</p></list-item><list-item><p>Invasion beyond subcutaneous tissue</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>AJCC-8 Staging System</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage Ti: In situ</p>
          </list-item>
          <list-item>
            <p>Stage T1: Tumor diameter less than 2 cm</p>
          </list-item>
          <list-item>
            <p>Stage T2: tumor diameter 2 to 3.9 cm</p>
          </list-item>
          <list-item>
            <p>Stage T3:
<list list-type="bullet"><list-item><p>Tumor diameter of at least 4 cm</p></list-item><list-item><p>Minor bone&#x000a0;erosion</p></list-item><list-item><p>Perineural invasion at least 0.1 mm or&#x000a0;invading a nerve located deeper than the dermis</p></list-item><list-item><p>Invasion&#x000a0;beyond subcutaneous tissue</p></list-item><list-item><p>Invasion greater than 6 mm depth</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Stage T4A: Gross cortical bone or marrow invasion</p>
          </list-item>
          <list-item>
            <p>Stage T4B: Skull invasion or skull base foramen involvement&#x000a0;<xref ref-type="bibr" rid="article-29094.r1">[1]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29094.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for localized disease is generally excellent. The overall mortality rate for cutaneous squamous cell carcinoma is approximately 1% to 2%,<xref ref-type="bibr" rid="article-29094.r11">[11]</xref>&#x000a0;with approximately 3% of cases metastasizing.<xref ref-type="bibr" rid="article-29094.r12">[12]</xref>&#x000a0;The lymph nodes are the most common site of metastasis.<xref ref-type="bibr" rid="article-29094.r2">[2]</xref>&#x000a0;Cases involving single node metastasis up to 3 cm are associated with a 90% disease-specific 5-year survival.<xref ref-type="bibr" rid="article-29094.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-29094.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of cutaneous squamous cell carcinoma include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Metastases</p>
          </list-item>
          <list-item>
            <p>Local invasion</p>
          </list-item>
          <list-item>
            <p>Pain</p>
          </list-item>
          <list-item>
            <p>Loss of function</p>
          </list-item>
          <list-item>
            <p>Poor&#x000a0;cosmesis</p>
          </list-item>
          <list-item>
            <p>Death</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29094.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The American Academy of Dermatology (AAD) recommends the following preventative measures for patients:</p>
        <list list-type="bullet">
          <list-item>
            <p>Individuals should limit sun exposure during peak UV index hours.</p>
          </list-item>
          <list-item>
            <p>Sunscreen with at least SPF 30 should be regularly used and reapplied every 2 hours and even after swimming or excessive sweating.</p>
          </list-item>
          <list-item>
            <p>Protective clothing and sunglasses should always be worn when exposed to sunlight.</p>
          </list-item>
          <list-item>
            <p>Annual full-body skin exams are recommended for the general adult population, with more frequent exams suggested for patients with significant risk factors (AAD,&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.aad.org/public/everyday-care/sun-protection/shade-clothing-sunscreen">Shade, Clothing, and Sunscreen</ext-link>).</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29094.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Due to the strong association with UV radiation, photoprotection is crucial in reducing the risk of developing cutaneous squamous cell carcinoma. Healthcare professionals should advise patients on photoprotective measures. Annual full-body skin exams are recommended,&#x000a0;with more frequent exams advised for patients with significant risk factors. Referral to radiation or surgical oncology, urology, gynecology, or otolaryngology may be necessary for comprehensive management in advanced cases.<xref ref-type="bibr" rid="article-29094.r28">[28]</xref></p>
      </sec>
      <sec id="article-29094.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29094&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29094">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/cutaneous-squamous-cell-carcinoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29094">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29094/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29094">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-29094.s17">
        <fig id="article-29094.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Cutaneous Squamous Cell Carcinoma. Cutaneous squamous cell carcinoma is typically characterized by a scaly, erythematous, or hyperpigmented papule or plaque. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="squamous__cell__carcinoma" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-29094.s18">
        <fig id="article-29094.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Histological Slide of Cutaneous Squamous Cell Carcinoma. Tumors classically consist of atypical keratinocytes with abundant eosinophilic or pink, glassy cytoplasm. Contributed by F Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="673-20019" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-29094.s19">
        <fig id="article-29094.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Histological Slide of Squamous Cell Carcinoma, Acantholytic. This subtype is characterized by clefting around nests or cords of plump, polygonal tumor cells, creating a glandular appearance. Contributed by D Anand, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="scc__acantholytic" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-29094.s20">
        <fig id="article-29094.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Histological Slide of Squamous Cell Carcinoma, Sarcomatoid. Spindle-shaped keratinocytes with pleomorphic nuclei are haphazardly arranged throughout the dermis, typically with an infiltrative pattern. Contributed by D Anand, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sarcomatoid__scc" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-29094.s21">
        <fig id="article-29094.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Histological Slide of Squamous Cell Carcinoma, Positive p40 Stain. Atypical fibroxanthoma is an important histological differential that typically stains negative for p63 and p40, in contrast to sarcomatoid or spindle squamous cell carcinoma. Contributed by D Anand, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="scc__p40" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-29094.s22">
        <fig id="article-29094.image.f6" position="float" orientation="portrait">
          <caption>
            <p>Histological Slide of Squamous Cell Carcinoma, in Situ. Full-thickness keratinocyte atypia has not invaded beyond the basal layer of the epidermis, unlike invasive squamous cell carcinoma, which penetrates beyond the basal layer. Contributed by D Anand, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="SCCIS__bowen" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-29094.s23">
        <fig id="article-29094.image.f7" position="float" orientation="portrait">
          <caption>
            <p>Histological Slide of Squamous Cell Carcinoma, Clear Cell. This subtype is characterized by clear or pale tumor cells, which may or may not demonstrate an epidermal connection. Contributed by D Anand, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="scc__clear__cell" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-29094.s24">
        <fig id="article-29094.image.f8" position="float" orientation="portrait">
          <caption>
            <p>Histological Slide of Squamous Cell Carcinoma, Keratoacanthoma. This subtype is characterized by a crateriform invagination filled with keratin. Contributed by D Anand, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="scc__keratoacanthoma" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-29094.s25">
        <title>References</title>
        <ref id="article-29094.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Que</surname>
                <given-names>SKT</given-names>
              </name>
              <name>
                <surname>Zwald</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Schmults</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>237</fpage>
            <page-range>237-247</page-range>
            <pub-id pub-id-type="pmid">29332704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caudill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Burkhart</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>The risk of metastases from squamous cell carcinoma of the skin.</article-title>
            <source>Int J Dermatol</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>483</fpage>
            <page-range>483-486</page-range>
            <pub-id pub-id-type="pmid">35324009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Que</surname>
                <given-names>SKT</given-names>
              </name>
              <name>
                <surname>Zwald</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Schmults</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>249</fpage>
            <page-range>249-261</page-range>
            <pub-id pub-id-type="pmid">29332705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Omland</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Ahlstr&#x000f6;m</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Gerstoft</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mohey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kronborg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kvinesdal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gniadecki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Obel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Omland</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Risk of skin cancer in patients with HIV: A Danish nationwide cohort study.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>689</fpage>
            <page-range>689-695</page-range>
            <pub-id pub-id-type="pmid">29588249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaju</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Ransohoff</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Sarin</surname>
                <given-names>KY</given-names>
              </name>
            </person-group>
            <article-title>Familial skin cancer syndromes: Increased risk of nonmelanotic skin cancers and extracutaneous tumors.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>74</volume>
            <issue>3</issue>
            <fpage>437</fpage>
            <page-range>437-51; quiz 452-4</page-range>
            <pub-id pub-id-type="pmid">26892653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coggshall</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Farsani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ruben</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>McCalmont</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Shinkai</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Keratitis, ichthyosis, and deafness syndrome: a review of infectious and neoplastic complications.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>127</fpage>
            <page-range>127-34</page-range>
            <pub-id pub-id-type="pmid">23384797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Williams</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Dreyer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fillman</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <chapter-title>Porokeratosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">30335323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bleeker</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Overbeek</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>van Beurden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berkhof</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Lichen Sclerosus: Incidence and Risk of Vulvar Squamous Cell Carcinoma.</article-title>
            <source>Cancer Epidemiol Biomarkers Prev</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>1224</fpage>
            <page-range>1224-30</page-range>
            <pub-id pub-id-type="pmid">27257093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Lanna</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>BNM</given-names>
              </name>
              <name>
                <surname>de Melo</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Bonamino</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>LDB</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>LFR</given-names>
              </name>
              <name>
                <surname>Cardoso</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Boroni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cohen Goldemberg</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Oral Lichen Planus and Oral Squamous Cell Carcinoma share key oncogenic signatures.</article-title>
            <source>Sci Rep</source>
            <year>2022</year>
            <month>Nov</month>
            <day>30</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>20645</fpage>
            <pub-id pub-id-type="pmid">36450755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muzic</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Alniemi</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Zubair</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Olazagasti Lourido</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sosa Seda</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Incidence and Trends of Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma: A Population-Based Study in Olmsted County, Minnesota, 2000 to 2010.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>92</volume>
            <issue>6</issue>
            <fpage>890</fpage>
            <page-range>890-898</page-range>
            <pub-id pub-id-type="pmid">28522111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wehner</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Cidre Serrano</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Nosrati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schoen</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Chren</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Boscardin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Linos</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>All-cause mortality in patients with basal and squamous cell carcinoma: A systematic review and meta-analysis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>78</volume>
            <issue>4</issue>
            <fpage>663</fpage>
            <page-range>663-672.e3</page-range>
            <pub-id pub-id-type="pmid">29146125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karia</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schmults</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>68</volume>
            <issue>6</issue>
            <fpage>957</fpage>
            <page-range>957-66</page-range>
            <pub-id pub-id-type="pmid">23375456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parekh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Seykora</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous Squamous Cell Carcinoma.</article-title>
            <source>Clin Lab Med</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>503</fpage>
            <page-range>503-525</page-range>
            <pub-id pub-id-type="pmid">28802498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neagu</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>&#x00162;igli&#x0015f;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Botezatu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Enache</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cobilinschi</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>V&#x000e2;lcea-Precup</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Grin&#x00162;escu</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Clinical, histological and therapeutic features of Bowen's disease.</article-title>
            <source>Rom J Morphol Embryol</source>
            <year>2017</year>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-40</page-range>
            <pub-id pub-id-type="pmid">28523295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henderson</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Torres-Cabala</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Curry</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bassett</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Ivan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Prieto</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Tetzlaff</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>p40 is more specific than p63 for the distinction of atypical fibroxanthoma from other cutaneous spindle cell malignancies.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>1102</fpage>
            <page-range>1102-10</page-range>
            <pub-id pub-id-type="pmid">25029117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Idriss</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Barbosa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Vidal</surname>
                <given-names>NY</given-names>
              </name>
            </person-group>
            <article-title>Concomitant hypertrophic lichen planus and squamous cell carcinoma: Clinical features and treatment outcomes.</article-title>
            <source>Int J Dermatol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>61</volume>
            <issue>12</issue>
            <fpage>1527</fpage>
            <page-range>1527-1531</page-range>
            <pub-id pub-id-type="pmid">35766459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mufti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sachdeva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maliyar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sibbald</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Squamous cell carcinoma arising within discoid lupus erythematous lesions: A systematic review.</article-title>
            <source>JAAD Int</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>2</volume>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">34409345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Ad Hoc Task Force</collab>
              <name>
                <surname>Connolly</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Coldiron</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Fazio</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Storrs</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Vidimos</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Zalla</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Smith Begolka</surname>
                <given-names>W</given-names>
              </name>
              <collab>Ratings Panel</collab>
              <name>
                <surname>Berger</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Bigby</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bolognia</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Brodland</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cronin</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Dahl</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Grant-Kels</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hanke</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Hruza</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Lober</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>McBurney</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Norton</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Roenigk</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Wheeland</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Wisco</surname>
                <given-names>OJ</given-names>
              </name>
            </person-group>
            <article-title>AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>531</fpage>
            <page-range>531-50</page-range>
            <pub-id pub-id-type="pmid">22959232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowe</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1992</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>976</fpage>
            <page-range>976-90</page-range>
            <pub-id pub-id-type="pmid">1607418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chren</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Linos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Stuart</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Parvataneni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boscardin</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma.</article-title>
            <source>J Invest Dermatol</source>
            <year>2013</year>
            <month>May</month>
            <volume>133</volume>
            <issue>5</issue>
            <fpage>1188</fpage>
            <page-range>1188-96</page-range>
            <pub-id pub-id-type="pmid">23190903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of nonexcisional treatment modalities for superficially invasive and in situ squamous cell carcinoma: A systematic review and meta-analysis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>87</volume>
            <issue>1</issue>
            <fpage>131</fpage>
            <page-range>131-137</page-range>
            <pub-id pub-id-type="pmid">34375669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nestor</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cognetta</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cockerell</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Glick</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Consensus Guidelines on the Use of Superficial Radiation Therapy for Treating Nonmelanoma Skin Cancers and Keloids.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>12</fpage>
            <page-range>12-18</page-range>
            <pub-id pub-id-type="pmid">30881578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mager</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gardeen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carr</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Shahwan</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives.</article-title>
            <source>Clin Cosmet Investig Dermatol</source>
            <year>2023</year>
            <volume>16</volume>
            <fpage>2135</fpage>
            <page-range>2135-2142</page-range>
            <pub-id pub-id-type="pmid">37581012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harrington</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Burtness</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Greil</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Souli&#x000e8;res</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tahara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Castro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Psyrri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brana</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bast&#x000e9;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Neupane</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bratland</surname>
                <given-names>&#x000c5;</given-names>
              </name>
              <name>
                <surname>Fuereder</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>BGM</given-names>
              </name>
              <name>
                <surname>Mesia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ngamphaiboon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rordorf</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wan Ishak</surname>
                <given-names>WZ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gumuscu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Swaby</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Rischin</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2023</year>
            <month>Feb</month>
            <day>01</day>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>790</fpage>
            <page-range>790-802</page-range>
            <pub-id pub-id-type="pmid">36219809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis.</article-title>
            <source>Oncotarget</source>
            <year>2017</year>
            <month>Oct</month>
            <day>10</day>
            <volume>8</volume>
            <issue>47</issue>
            <fpage>83280</fpage>
            <page-range>83280-83291</page-range>
            <pub-id pub-id-type="pmid">29137342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohan</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.</article-title>
            <source>JAMA Dermatol</source>
            <year>2016</year>
            <month>May</month>
            <day>01</day>
            <volume>152</volume>
            <issue>5</issue>
            <fpage>527</fpage>
            <page-range>527-32</page-range>
            <pub-id pub-id-type="pmid">26914338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Arcy</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Pfeiffer</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Cahoon</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Arron</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Brownell</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cowen</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Israni</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Triplette</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Yanik</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Engels</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States.</article-title>
            <source>JAMA Dermatol</source>
            <year>2020</year>
            <month>Jul</month>
            <day>01</day>
            <volume>156</volume>
            <issue>7</issue>
            <fpage>772</fpage>
            <page-range>772-779</page-range>
            <pub-id pub-id-type="pmid">32401271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29094.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waldman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Grant-Kels</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>The role of sunscreen in the prevention of cutaneous melanoma and nonmelanoma skin cancer.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>80</volume>
            <issue>2</issue>
            <fpage>574</fpage>
            <page-range>574-576.e1</page-range>
            <pub-id pub-id-type="pmid">30012373</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
